One big takeaway from Trump’s speech? He needs a weak dollar.
Brett Arends is an award-winning financial writer with many years experience writing about markets, economics and personal finance. He has received an individual award from the Society of American Business Editors and Writers for his financial writing, and was part of the Boston Herald team that won two others. He has worked as an analyst at McKinsey Co., and is a Chartered Financial Consultant. His latest book, “Storm Proof Your Money”, was published by John Wiley Co.
When it comes to Social Security ‘fraud,’ Trump will have to put up or shut up
Brett Arends is an award-winning financial writer with many years experience writing about markets, economics and personal finance. He has received an individual award from the Society of American Business Editors and Writers for his financial writing, and was part of the Boston Herald team that won two others. He has worked as an analyst at McKinsey Co., and is a Chartered Financial Consultant. His latest book, “Storm Proof Your Money”, was published by John Wiley Co.
There’s a price war over weight-loss drugs as Wegovy cuts costs for monthly subscribers
Published:
Novo Nordisk said game on, as the Denmark-based drugmaker lowered prices on its obesity treatment Wegovy for those without insurance, and said it would deliver the drug to their homes.
The company’s
NVO move comes a week after Eli Lilly & Co. LLY cut prices for its rival weight-loss drug Zepbound.